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Abstract This article will review the recent advances in the
understanding of the role of epigenetic modifications and the
promise of future epigenetic therapy in neurodegenerative
dementias, including Alzheimer’s disease and frontotemporal
dementia.
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Background
Alzheimer’s disease and frontotemporal dementia
Alzheimer’s disease (AD) and frontotemporal dementia (FTD)
are two of the most common neurodegenerative disorders and
are the leading causes of neurodegenerative dementia [1–3].
Current therapeutics designed to treat AD have not been suc-
cessful in effectively treating the progressive nature of cognitive
decline observed in patients. Cholinesterase inhibitors
donepezil, rivastigmine and galantamine, huperzine-A, and N-
methyl-D-aspartate antagonist memantine are approved drugs
available for AD; however, these drugs fail to treat the under-
lying cause of neurodegeneration and only provide modest
short-term symptomatic relief [4]. Clinical trials to test drugs
designed to reduce levels of abnormal protein accumulation and
other pathophysiological mechanisms of AD have failed. Food
and Drug Administration (FDA)-approved drugs designed to
treat the causes of FTD are currently unavailable [5]. One of the
underlying reasons for the failure of treatment measures is the
lack of knowledge pertaining to the epigenetic, environmental,
and mechanistic drivers of neurodegeneration.
Many studies have focused on determining the genetic
contributions to AD and FTD. AD pathology is typically
characterized by the presence of intracellular neurofibrillary
tangles, including phosphorylated microtubule associated pro-
tein tau (MAPT) and extracellular plaques, including aggre-
gated amyloid beta (Aβ) [6–8]. In familial forms of AD,
autosomal dominant mutations in APP, PSEN1 , and PSEN2
(all genes involved in the production of Aβ [9, 10]) are mainly
responsible for the early onset (younger than 65 years) form of
the disease. Recently, TREM2 was designated as another rare
monogenetic candidate for early onset of disease risk [11].
However, these mutations represent a very small percentage
of cases, and 90–95 % of cases are nonfamilial and late onset
(>65 years old) [12]. Multiple studies conducted to determine
disease-causative loci have revealed that AD is highly complex
and heterogeneous in nature; susceptibility loci vary according
to gene penetrance, ethnicity, geography, environment, and
sample size of various studies; therefore, identifying genes
responsible for late onset of disease is highly challenging
[13–15]. Linkage and genome-wide association studies have
mapped regions in chromosomes 9, 10, and 12 that are asso-
ciated with AD risk; several genes, such as APOE , BACE1 ,
and BACE2 , for example, are thought to be prime candidates
to confer risk because of their role in pathways associated with
Aβ biosynthesis and deposition [16]. However, approximately
300 genes have been implicated without strong causative
evidence to increase risk for AD [14]. Therefore, nongenetic
factors, such as epigenetic modifications, may also be causa-
tive and are currently the subject of intense research.
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FTD is a leading cause of dementia after AD and is more
common among those below the age of 65 years. FTD shares
common susceptibility genes and potentially similar molecu-
lar pathways with other neurodegenerative disorders, such as
amyotrophic lateral sclerosis, corticobasal degeneration, and
progressive supranuclear palsy. Based on the clinical spec-
trum, FTD is divided into 3 syndromes: behavioral, semantic,
and nonfluent variants [17]. Similar to AD, FTD patients
present abnormal accumulation of proteins in the brain [18].
FTD is classified under an umbrella condition known as
frontotemporal lobar degeneration (FTLD). Based on the pa-
thology and type of protein inclusions involved, FTLD is
classified into FTLD-Tau, FTLD-TDP43, and FTLD-FUS
(reviewed in [5]). Several causal mutations have been identi-
fied in FTD. Mutations in MAPT and the growth factor
progranulin (GRN) account for nearly 50 % of familial FTLD
cases. Mutations in C9ORF72 account for nearly 25 % of
familial FTD [19]. Other rare mutations have been found in
DNA and RNA binding proteins (e.g., TDP-43, FUS),
charged multivesicular body protein 2B (CHMP2B) and
vesicle-transport protein; these mutations account for less than
5 % of familial cases [18]. It must be noted that CHMP2B is
also known as chromatin modifying protein 2B, which may
suggest an epigenetic contribution to disease. However, cur-
rent studies point to the abnormal protein trafficking and
degradation functions associated with CHMP2B that may
contribute to neurodegeneration in FTD [20, 21].
The majority of FTD cases are sporadic and the molecular
causative factor in most patients is unknown. Like for AD,
other nongenetic factors may also contribute to the pathoge-
nicity of the disease. Large-scale genome-wide association
studies have identified a number of risk-associated variants
in AD and, to a lesser extent, in FTD (reviewed in [22, 23]).
Also, interestingly, with respect to this review, functional
screens for modifiers of MAPT have revealed several chro-
matin binding proteins and a histone variant [24], some of
which may play a role in disease further raising the potentially
critical role of epigenetics in AD and FTD.
Neuroepigenetics
Background and Motivation
Epigenetics is the study of changes in gene expression and/or
chromatin structure and cell function, caused by mechanisms
other than changes in the underlying DNA sequence [25].
This field is an important area of investigation because epige-
netic modifications may explain differential regulation of AD
and FTD risk genes and genomic regions, without changes to
their DNA sequence and therefore undetected in genetic stud-
ies. These modifications can occur on DNA molecules (main-
ly on cytosine bases at citosine-guanine (CpG) sites) or on
histone proteins, which make up the fundamental structure of
chromatin [26, 27]. Modifications to histones include meth-
ylation, acetylation, phosphorylation, ubiquitination,
sumoylation, etc., and more than 100 different modification
residues have been characterized [28]. Recently, several ad-
ditional new histone medications and histone amino acid
target residues have been described in the brain, adding to
the repertoire and complexity of histone modifications; often,
histone and DNA modifications occur in a multitude of
various combinations to control gene transcription and chro-
matin architecture resulting in a highly complex, context-
dependent, and specific regulation of the genome [28–30].
DNA methylation and histone modifications together regu-
late chromatin structure, which, in turn, regulates gene ex-
pression by facilitating access to DNA regulatory elements.
Recently, noncoding RNAs (ncRNAs), such as long non-
coding RNAs (lncRNAs) and microRNAs (miRs), among
other regulatory RNA molecules, have been shown to play
an epigenetic role in the regulation of genes by various
mechanisms, including recruiting DNA methyltransferases
and chromatin modifiers to their targets, inhibiting transla-
tion of mRNA, and in the degradation or stability of mRNA
by sequence complementarity with their targets [31]. Epige-
netic modifications are therefore central facilitators of the
nexus between genes and the environment. The specific roles
of DNA methylation, histone modifications, and ncRNAs in
AD and FTD will be discussed in later sections.
The role of epigenetic modifications has been studied in
various fields of biology, especially in developmental and
cancer biology; erroneous regulation of epigenetic modifica-
tions has been linked to many developmental deficiencies,
including neurogenesis, and in the formation and progression
of cancer [32, 33].
Unlike mutations and other genetic abnormalities, which
are largely stable in the genome throughout life, epigenetic
modifications are dynamic and potentially reversible with the
use of drugs and therapeutic approaches [34]. Therefore, with
the understanding of the epigenetic contribution to neurolog-
ical diseases, new therapeutic approaches can be potentially
designed to reverse aberrant epigenomes—an active area of
research in oncology and other fields.
Until recently, epigenetic regulation of neuronal processes
was not considered a critical area of study because dynamic
changes in the “neuro-epigenome”were not expected to occur
in postmitotic neuronal cells. However, several key observa-
tions have indicated epigenetic modifications and their regu-
lation play a critical role in the development of the nervous
system, as well as in aging and the decline of cognitive
processes [35–37]. The dynamic nature of epigenetic marks
lend themselves mechanistically to the regulation of neuronal
processes during stimulation and maintenance of synaptic
plasticity during learning and memory formation, which occur
within relatively short time spans [38–40].
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During development, neuronal genes expressed during
neurogenesis are repressed in other lineages by epigenetic
mechanisms. Neuronal genes contain a repressor element in
their promoters, which are then recognized by proteins com-
plexes containing histone deacetylases (HDACs) [41];
deacetylation of histones in the promoter region subsequently
results in promoter DNA methylation leading to gene repres-
sion. Trimethylation of lysine 27 on histone H3, H3K27me3,
and other epigenetic modifications plays an important role in
neuronal development during embryogenesis by orchestrating
repression and/or expression of genes required for the neuronal
lineage and subsequent differentiation [42]. Several studies
have shown that epigenetic modifications are dynamic in post-
natal brains and throughout the aging process [43, 44]. 5-
methylcytosine (5-mc) and 5-hydroxymethylcytosine (5-hmc)
levels in the brain increase with age at promoters associated
with neurodegenerative diseases [45]. Several post-translational
modifications of histones, mainly histone methylation and acet-
ylation, drift with age and are associated with age-related
decline in cognitive and memory related process [46, 47].
The roles of epigenetic readers, writers, and erasers in neu-
rological disease are also becoming clearer: mutations in DNA
methylation writers and their regulators result in a number of
neurological disorders, including Rett syndrome and autism
(MECP2) [48, 49], hereditary sensory and autonomic neurop-
athy 1 with adult-onset dementia [DNA methyltransferase 1
(DNMT1)] [50], and immunodeficiency, centromeric instabili-
ty, and facial anomaly (ICF1/2; DNMT2B and ZBTB24) [51,
52]. Similarly, mutations in histone-modifying enzymes have
been implicated in neurological disorders. Mutations in epige-
netic writers (e.g., histone lysine methyltransferases MLL1 ,
KMT1C and KMT6A) have been associated with loss of mem-
ory and learning, schizophrenia, and cognitive and neuro-
developmental defects [53–55]. Similarly, mutations in epige-
netic erasers (e.g., lysine demethylases KDM5C , JARID1C ,
SMCX , and JMJD3) result in disorders such as mental retarda-
tion, autism, and abnormal neurogenesis [56–58]. Addiction
and other external environmental agents also cause chromatin
modification differences in the brain [47]. Along with the
aforementioned defects in epigenetic readers and writers, his-
tone acetylation regulation [catalyzed by histone acetyltrans-
ferases (HATs)] and its interaction with other epigenetic marks
are critical components in the maintenance of neuronal plastic-
ity and memory [59]. Histone acetylation regulation is an
important avenue for epigenetic therapy because of its funda-
mental role in cognition and memory, and the promise of
HDAC inhibitors (HDACi) as general neuroprotective agents.
More recently, ncRNAs have been associated with neuro-
nal development, differentiation, and disease [60]. miR–
processing proteins, like Dicer, and several miR transcripts
play an important role in the differentiation of neuronal stem
cells by targeting transcription factors and other proteins re-
sponsible for programmed differentiation and maintaining
cellular identity. lncRNAs also play a vital role in neuro-
genesis [61]. One study found more than 1300 lncRNAs
associated with brain development and region-specific expres-
sion, many of which are associated with recruitment of chro-
matin remodeling complexes [62]. The interaction of ncRNA
with epigenetic remodelers is another potential avenue for
therapeutic intervention for neurological disorders. In the
context of memory maintenance and synaptic plasticity,
ncRNA molecules and their processing and regulatory mech-
anisms are important in maintaining homeostasis of cognitive
processes [63]. Importantly, defective ncRNA pathways may
lead to neurodegenerative diseases, psychiatric disorders, and
brain cancer. The regulation of brain-derived neurotrophic
factor (BDNF) by BDNF-antisense (BDNF-AS ) transcript,
lncRNA SCAANT1 transcribed from the mutated expansion
locus in spinocerebellar ataxia 7, FMR1 locus associated
lncRNA in fragile X syndrome, and dendritic plasticity factor
DPP1 regulating ncRNA are some select examples of
ncRNA-mediated regulation of neurological function and dis-
ease; detailed reviews on the role of ncRNAs in neurological
function and disease have been published recently [64–66].
Overall, epigenetic modifications play a major role in both
neurogenesis and maintaining long-term activity and the ho-
meostasis of cognitive processes in the adult brain, and may
result in neurological disease when dysregulated. Epigenetic
therapy holds great promise in that several small molecules
and environmental modulation have been shown to success-
fully reverse several epigenetic marks and disease symptoms
in both laboratory and clinical settings. Several epigenetic
drugs (DNMTand HDAC inhibitors [DNMTi, HDACi]) have
been approved by the FDA for use in cancer and others are
currently in clinical trials [67, 68]. However, given the central
role epigenetic modifications play in neuronal cells, the po-
tential use of these approved drugs and future drugs to treat
neurodegenerative disorders is very promising.
Mechanistically, epigenetic therapeutics must address the
complex and intricate cross-talk between various epigenetic
modifications, while minimizing the risk of altering other
biological processes and pathways. In the next section, we
will address potential targets of therapy specific to AD and
FTD, and the promise of epigenetic medicine in treating faulty
epigenetic processes that lead to neurodegeneration.
Avenues of Epigenetic Therapy in AD and FTD
DNA Methylation-based Therapy
Several groups have investigated the role of DNAmethylation
at specific AD risk loci and also the genome-wide DNA
methylation profile differences between AD patients and con-
trols. Owing to the relative lack of postmortem human tissues,
many studies have used cell lines, patient samples, and animal
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models to determine changes in DNA methylation. Environ-
mental and extra-cellular factors, and the deregulation of
epigenetic readers, writers, and readers are primary causes of
aberrant DNA methylation patters in the genome. Several
epigenetic therapeutic strategies have been proposed based
on the DNA methylation profile changes that typically occur
at risk loci.
Genes associated with Mendelian forms of dementia, such as
APP, PSEN1 , andMAPT, showed no clear differences in DNA
methylation between AD patients and controls in multiple stud-
ies [44, 69, 70], and high-throughput studies have failed to detect
large differences in methylation profiles between cases and
controls [71]. However, small differences in DNA methylation
alongwith age-related epigenetic drift may play a role in AD risk
over time. A study conducted to determine theDNAmethylation
state of repetitive elements inADpatients comparedwith healthy
controls found elevated LINE-1 element DNA methylation,
83.9 % vs 83.1 % respectively (p=0.05) [72].
In cerebral endothelial cells, under high Aβ conditions, the
promoter region of discoidin domain receptor 1 (DDR1) is
hypermethylated.DDR1 is involved in the degradation of Aβ
[73]. Age-related decreases in DDR1 expression, explained
partly by promoter DNA methylation increases, may play a
contributing role in the pathogenicity of AD by reduced
degradation of Aβ [74]. Lung cancer associated gene
S100A2 , related to the neurotrophic factor S100B , showed
increased DNA methylation in AD cases compared with
normal patients. In the same study, cell adhesion protein
SORBS3 showed hypermethylation in AD [44].
In FTD, data for global epigenetic differences between
patients and controls from large sample sizes are currently
unavailable. However, several studies have focused on individ-
ual risk genes to determine disease-related DNA methylation
differences. No significant differences were detected in meth-
ylation levels ofMAPT, APP, and PSEN1 in postmortem brain
from AD and FTLD-spectrum cases [69]; however, significant
differences in GRN methylation levels were detected, with the
GRN promoter hypermethylated in FTD vs controls (61.5% vs
46.3 %) [75]. The G4C2 repeat expansion in the C9ORF72
gene is a common cause of ALS and FTLD [19]. A recent study
found a proximal region of the repeat expansion to be
hypermethylated in patients compared with controls, and asso-
ciated with the presence of the repeat expansion [76].
Overall, DNA methylation appears to play a role in differ-
entiating AD and FTD samples from control at a few risk loci
and LINE-1 repeat elements. Additionally, several experi-
ments have further demonstrated that changing the environ-
mental conditions that affect the DNA methylation pathways
may induce dynamic epigenetic and expression changes at
genes associated with AD and FTD risk.
In mammalian and cell line models, modulating the
bioavailability of methionine synthesis factors resulted in
the differential methylation and expression of the AD risk
genes, PSEN1 and APP. Reducing the uptake of vitamin B12
and folate caused hypomethylation of the PSEN1 promoter and
increased its expression along with reduced DNA de novo
methylation; reducing the S-adenosylmethionine (SAM)/ S-
adenosylhomocysteine (SAH) ratio also resulted in the
hypomethylation of PSEN1 and APP while inhibiting
DNMT1 activity [77–81]. Interestingly, the environmental
toxin lead caused similar differential expression and
hypomethylation at risk loci [82, 83]. In neuroblastoma cells,
activation of mitogen-activated protein kinase pathways by
cellular stress (by anisomycin) caused Aβ overproduction and
APP, PSEN1 , and BACE1 hypomethylation accompanied by
histone H3 hyperacetylation and lower expression of HDACs
[84]. In human brains, hypermethylation of neurotrophic fac-
tors BDNF and cyclic adenosine monophosphate response
element-binding protein, and hypomethylation of pro-
inflammatory regulator nuclear factor kappa b were observed
and provided evidence for the involvement of epigenetic mod-
ifications in maintaining synaptic plasticity [85]. Ten-eleven
tanslocation (TET) proteins are responsible for converting
5-mc to 5-hmc and belong to a family of proteins that include
oxidative stress-responsive genes [86]. It is possible that TET
proteins might play a role in hypomethylation of AD risk genes
during aging and cellular stress. Further evidence for the envi-
ronmental influence for AD pathogenicity comes from mono-
zygotic twin studies, where the AD twin showed reduced DNA
methylation in the temporal neocortex compared with the non-
AD twin [87]. Therefore, minor epigenetic drift caused by
environmental toxins and cellular stress at genes such as APP
and Aβ overproduction may induce hypomethylation at other
AD risk loci and heighten the epigenetic disposition to AD in a
positive feedback loop. Therefore, future DNA methylation
targeted epigenetic therapy strategies must address the contrib-
uting factors that may cause age-related drifts in the DNA
methylation profiles.
In AD, the hypomethylation of APP, PSEN1 , and MAPT
promoters could be reversed by modulating the bioavailability
of methionine by increasing the levels of B12, folate, and
other methionine sources in the diet. The increased level of
methyl donor SAM (high SAM/SAH ratio) has been shown to
decrease the levels of PSEN1 expression, possibly by promot-
er hypermethylation, and reverse the hypomethylation-driven
higher expression of APP [77–81]. More studies are required
to determine the role of TET proteins and the conversion of 5-
mc to 5-hmc during the hypomethylation of AD gene pro-
moters. In the future, specific DNMT and TET inhibitors,
along with controlled methionine nutritional uptake, could
be used to modulate methylation of AD risk loci and in genes
involved in maintaining neural plasticity, especially during
episodes of cellular stress in the brain during injury or disease.
DNMT inhibitors (DNMTi) include azacitidine, decitabine,
and zebularine. Azacitidine and decitabine have been FDA
approved for use in leukemia [68]. These molecules are
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analogs of cytosine and are incorporated during cell division
and then function to sequester and inhibit DNMTs, therefore
reducing levels of DNA methylation in rapidly dividing can-
cer cells. In FTD and AD, genes such as GRN, BDNF, cyclic
adenosine monophosphate response element-binding protein,
and C9ORF72, are hypermethylated and repressed, possibly
contributing to the pathogenicity of the disease, and are po-
tential targets for DNMTi-based therapies. A study in
Friedreich ataxia, an autosomal recessive disease, used
DNMTi to reverse the hypermethylation associated with a
trinucleotide repeat expansion at the FXN locus; the study
revealed a modest effect in mouse cells, but the treatment was
ineffective in human Friedreich ataxia cells (reviewed in [88]).
However, cell lines derived from fragile X patients showed
beneficial effects of 5-azadeoxycytidine treatment [89]. Im-
portantly, the same group also demonstrated that combined
administration of DNMTi and other chromatin modifier in-
hibitors acted synergistically in the reactivation of the FMR1
gene, which is hypermethylated in patients [90].
Histone Modification Targeted Therapy
Epigenetic therapeutics targeting histone methylation and acet-
ylation is a promising strategy to treat loss of synaptic plasticity
and neurodegeneration. Histone acetylation plays a dynamic
role during synaptic stimulation and the maintenance of syn-
aptic plasticity [59]. Histone methylation, as described in the
previous sections, is associated with multiple neurological dis-
orders. Histone acetylation and methylation are better candi-
dates for targeted epigenetic therapy compared to DNMTi
because multiple protein families and complexes target specific
histone modifications to specific locations in the genome [28,
46, 91]. Similarly, multiple proteins are involved in the removal
of certain marks from histones [27, 68, 92–94]. A recent study
in pancreatic and liver cells demonstrated that histone methyl-
ation acts in a tissue- and gene-specific manner compared with
histone acetylation. For example, G9a/GLP is a histone H3
lysine 9 tri-methyltransferase (repressive mark) and the inhibi-
tion of the complex by a small molecular inhibitor selectively
upregulated cholesterol synthesis genes in pancreas, but not
liver, cells [95]. In contrast, HDACi deregulated hundreds of
genes irrespective of tissue type. More studies to investigate the
role of specific chromatin modifiers and complexes in
neurodegeneration may allow future drug designs to target
specific proteins involved in inducing neurodegeneration. For
example, a recent study identified deletions of KANSL1 , regu-
lator of histone H4 lysine 16 HAT KAT8 , as responsible for the
17q21.31 microdeletion syndrome, characterized by mental
retardation and delayed motor development [96]. Therefore,
the identification of other specific epigenetic regulators in-
volved in neurodegeneration will aid in the development of
novel chromatin mark modifying compounds. Recently, it was
shown that histone methylation plays a dynamic role in long-
term memory formation. Mice lacking the histone H3 lysine 4
trimethyltransferase MLL2 in the forebrain excitatory neurons
had impaired memory function in the hippocampus [97].
HATs play an important role in the maintenance of synaptic
plasticity and expression of neurotrophic factors. In mice,
fear-based contextual learning results in large increases in
the acetylation of histone H3; blocking the histone H3 acety-
lation pathway resulted in learning deficits; long-term poten-
tiation by stimulation resulted in increases of histones H3 and
H4 acetylation—in part by releasing HDAC2 from chromatin
and the activation in the promoter regions of neurotrophic
factors such as BDNF by the de-repression and release of
MECP2 (reviewed by [59, 92]). Loss of the HATs P300 and
CBP in mice models resulted in cognitive defects following
fear conditioning and reduced histone acetylation was ob-
served [38, 98].
HDACs fall into 4 main classes. Class I, II (a and b) and IV
are zinc-dependent, and class III is nicotinamide adenine
dinucleotide-dependent. In the memory-associated regions of
the brain, class I HDACs (HDACs 1, 2, 3, and 8), especially
HDAC2 and HDAC3, are more highly expressed than the
other HDACs [99]. Consequently, HDAC2 and HDAC3 have
been extensively studied for their role in memory formation
and loss. Knockout of HDAC2/3 resulted in better spatial
memory [100, 101]. Therefore, inhibiting the role of HDACs
in memory and cognitive impairments is a potential avenue of
epigenetic therapy. Several studies have been conducted to
characterize the effects of HDACi in AD and FTD models,
and have demonstrated improvements in long-term potentia-
tion and memory. In the cognitive decline observed in AD
mouse models, HDAC2 was expressed at higher levels in the
hippocampus and prefrontal cortex, even in the earliest stages
of disease, along with decreases in histone acetylation;
downregulation of HDAC2 restored plasticity and memory
formation, albeit during continued degeneration [102, 103].
HDAC2was also found to be elevated during stress and injury
in the brain, and resulted in the downregulation of genes
involved in memory and cognition [104].
More recent work has probed the roles of class II HDACs.
Class II HDACs are subdivided into class IIa, which includes
HDAC4, HDAC5, HDAC7, and HDAC9, which are charac-
terized by one catalytic site; class IIb proteins HDAC6 and
HDAC10 are characterized by two catalytic sites [105].
HDAC6, a cytoplasmic protein that interacts with MAPT,
was found to be elevated in AD patients [106]. Govindarajan
et al. [107] observed that a reduction of HDAC6 levels in the
APPPS1-21AD mouse model restored learning and memory,
as well as acetyl tubulin levels. They also observed that
HDAC6 reduction ameliorated mitochondrial trafficking in
this AD model, although these data did not clearly demon-
strate whether tubulin acetylation is actually a direct effect of
HDAC6-mediated neurotoxicity. Nevertheless, these data
warrant the need to investigate whether HDAC6 inhibitors,
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such as tubastatin A, can ameliorate the deficiencies observed
in AD mouse models. Kim et al. [108] probed the role of
HDAC4 and HDAC5, and observed that selective loss of
HDAC4, but not HDAC5, in the brain is detrimental to
learning and memory.
Several HDACi have been characterized. HDACi such as
carboxylic acids sodium butyrate, phenylbutyrate, and
valproic acid target class I and IIa HDACs with the most
efficacy; bacterial- and fungal-derived class 4 cyclic
tetrapeptides selectively inhibit class I HDACs; hydroxamic
acid trichostatin A (TSA), suberoylanilide hydroxamic acid
(SAHA) (FDA-approved in cancer) and its derivatives gener-
ally target class I and II [109]. However, it must be noted that
although SAHA (along with most other HDACs) is consid-
ered to be a pan-HDACi, it does not inhibit class IIa HDACs
at pharmacologically acceptable concentration ranges [110].
As opposed to the aforementioned HDACi, which do not
selectively target specific HDAC proteins, HDACi that are
members of the benzamide group, MS-275 and CI-994, spe-
cifically target HDAC1 and, to a lesser extent, HDAC3 [92].
Studies characterizing the roles of HDAC inhibition in synap-
tic plasticity in neurodegenerative models first emerged from
the laboratories of Tsai and colleagues. They demonstrated
that both an enriched environment and HDACi induce histone
tail acetylation, restore learning, and re-establish long-term
memory in a mouse model of neurodegeneration dependent
on the inducible neuronal expression of p25, a cell cycle
molecule [111]. In more recent studies, the role of HDAC2
in plasticity and memory was probed. HDAC2 negatively
regulates memory formation and synaptic plasticity [102].
Neuron-specific overexpression of HDAC2, but not HDAC1,
lead to decreased neuronal plasticity and impaired memory
formation. Conversely, HDAC2 knockout mice displayed
enhanced memory formation and exhibited improvement in
associative learning tasks [112]. Indeed, HDAC2 binds to
promoters of memory-related genes, such as BDNF and
FOS . SAHA administration improved associative learning
and ameliorated the deficiencies observed in the HDAC2-
overexpressing mice. In in vitro cellular models, mouse
models of AD, as well as in AD patients, HDAC2 mediates
an epigenetic blockade by binding and deacetylating the pro-
moters of genes important for learning and memory. This
blockade was reversed by HDAC2 knockdown [104]. The
studies implicating HDAC2 in AD pathology and the obser-
vation that it is possible to reverse the effects mediated by
HDAC2 through knockdown strategies advocate for the de-
velopment of HDAC2 selective inhibitors. The need for
HDAC2 selective inhibitors is critical, especially because the
data may explain the toxicities associated with pan-HDAC
inhibition by attributing the toxicity to the inhibition of some
HDACs, such as HDAC1, which may promote survival of
neurons. Indeed, the same group showed that p25-mediated
neuronal death involves sequestration of HDAC1 and
inhibition of its activity leads to double-stranded DNA breaks
and aberrant cell cycle re-entry [113].The exact mechanism
and specific targets regulated by HDAC1 remain undefined.
The use of HDACi in FTD is not as extensively studied as
AD, however the data available to date suggest that they may
be valuable therapeutic agents. In FTD, SAHA administration
in GRN haplo-insufficient patient cell lines restored GRN
expression to normal levels [114]. In this study, Cenik et al.
[114] attempted to identify which isoform is relevant for the
effectiveness of SAHA. They observed that class I HDAC
inhibitors such as MS-275 could induce GRN levels; howev-
er, the high concentrations required for such an effect did not
allow them to rule out cross reactivity with other HDACs.
HDAC6 inhibitors, such as tubastatin A and tubacin, however,
were not able to induce GRN levels. This suggests that it is
possible that inhibition of more than one isoform may be
required to restore GRN levels. A thorough molecular knock-
down approach may reveal the responsible HDACs.
Together, HDACi could potentially be used as potent and
selective inhibitors of HDACs involved in the progression of
memory decline and regulation of genes involved in AD and
FTD. These small molecules could also be used synergistically
in combination with DNMTi to improve specificity and en-
hance the reversal of the decline in neurological functions. In
fragile X, for example, the combination of DNMTi andHDACi
synergistically enhanced the reactivation of FMR1 [90].
Even though the majority of the focus on HDAC inhibition
has been on changes in gene expression through histone
acetylation, both the ability of multiple HDACs to shuttle
between cellular compartments and the huge number of cyto-
solic, mitochondrial, and nuclear proteins targeted by acetyla-
tion suggest that acetylation of multiple proteins other than
histones may be relevant for disease progression. For exam-
ple, acetylation ofMAPT inhibits the degradation of its phos-
phorylated form and contributes to tauopathies. Indeed,
MAPT acetylation is elevated in patients at early and moderate
stages of tauopathies [115].
The potential for HDAC inhibition as a therapeutic strategy
for AD and FTD is promising. However, there is an urgent
need for the development of isoform-selective inhibitors be-
cause the data available to date suggest an intricate interplay
between the different HDAC isoforms with only a subset
promoting toxicity. This alone may explain the toxicities
observed with pan-HDAC inhibition. For therapeutics in the
brain, the challenge of designing isoform-selective inhibitors
is compounded by the need for compounds that will readily
cross the blood–brain barrier (BBB). Moreover, it will also be
important to develop methods to test the selectivity of the
inhibitors other than determining the inhibition constant (Ki)
in test tubes. This has been problematic because the concen-
trations needed to see any effect in cell culture or in vivo
exceeds the measured Ki, complicating the interpretation of
the roles of the relevant HDACs and raising the possibility of
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off-target effects. The disconnect between the Ki measured in
test tubes and the concentrations used in vivo may be
explained by the cellular permeability of the compound, as
well as the competition with other HDACs in a cell, whereas
no such competition is available when the Ki is measured in
the test tube. One way to facilitate the interpretation of the
results obtained with HDAC inhibitors lies in possibly design-
ing compounds that have similar structures, but cannot inhibit
the specific HDACs targeted by the HDAC inhibitor.
ncRNATherapy Strategies
miRs are complementary short (20–23) nucleotide fragments
that are involved in the downregulation of the genes they
target. miR processing proteins are indispensible for
neurogenesis and have been implicated in AD and FTD path-
ogenesis [50, 116, 117]. Studies in human patients and cell
lines have led to the identification of miRs that target genes
involved in various pathways involved in neurodegeneration
[118]. Conditional knockout of miR processing protein Dicer
resulted in hyperphosphorylation of MAPT, a key pathophys-
iological feature of AD [119]. In AD models and patient
studies, the expression of miRs in different tissues and fluids
were found to be heterogeneous [120]. These miR expression
pattern changes were observed in different tissues of the brain
and suggested that the effects may be local and specific.
Several miRs are associated with regions of the brain affected
in AD. miRs also target kinase and acetylase pathways asso-
ciated with AD [119, 121]. Several miRs are differentially
regulated in different molecular pathways affecting AD
pathogenesis. Reduced expression of miR targeting genes such
as APP, BACE1 , and MAPT were detected (miRs
29,15,107,101,106, etc.), and miR that regulate neurotrophic
factors and immune system-related proteins were upregulated
(miRs 125b, 146a, 206, 181, 146, let-7b, etc.); comprehensive
reviews of particular miR differential expression in
neurodegeneration have been published recently [118, 122,
123, 124].
Recently it was shown that addition of Aβ to neural cul-
tures elicited differential expression of miR. In AD model
mice, reduced expression of miRs 103 and 107, which target
actin binding protein cofilin, resulted in the formation of rod-
like actin structures, typically found in AD patients [125].
However, it is unclear if differentially regulated miRs drive
AD pathogenesis or if they are a consequence of AD pathol-
ogy. In one study, overexpression of miR-29a and miR-29b-1
resulted in the reduced expression of BACE1 and Aβ produc-
tion [126]. miRs 107, 298, and 328 also target BACE1 and are
downregulated in AD [126, 127]. Similarly multiple miRs
interact with the Aβ precursor, APP [128, 129]. lncRNA
and small interfering RNA are other important class of
ncRNAs that may also be associated with AD. The
overexpression of the pathological isoform of Aβ, Aβ-42,
increased BACE1 antisense transcript lncRNA was detected
in AD and prevented miR-485-5p mediated repression of
BACE1 by masking the target sequence [130]. lncRNA also
function in recruiting epigenetic factors to their targets. There-
fore, altered lncRNA expression may play a role affecting the
epigenetic landscape at different parts of the genome. XIST is
a classic example of a lncRNA that promotes X chromosome
inactivation by recruiting repressive chromatin marks [131].
In the context of neurodegeneration, further studies are
required to determine differential expression of ncRNA in
AD and FTD brains, and their role in altering epigenetic
modifications. Together, pathways altering expression of
ncRNAs may affect the regulation of AD and FTD risk genes
and play a contributing role in the progression of disease.
Inflammatory, apoptotic, and RNA sequestration pathways
have been hypothesized to alter AD-associated ncRNA ex-
pression in addition to mRNA expression [122, 132–134].
Abnormal RNA sequestration may play a greater role in
FTLD because two types of FTD protein inclusions (FTLD-
TDP43 and FTLD-FUS) play a role in binding and dendritic
transport of mRNA and ncRNA, as well as in post-
transcriptional and translational regulation in the cell [122,
135]; increased cytoplasmic TDP-43 and FUS relocation due
to stress or mutations and resulting inclusions in FTD pathol-
ogy may therefore play a role in neurodegeneration, in part
owing to erroneous processing of associated RNA transcripts.
Identification of RNA transcripts associated with TDP-43 and
FUS may serve as targets for exogenous RNA therapy. In
addition, TDP-43 interacts with miR processing Dicer com-
plex and regulates a subset of miR and is required for neuronal
outgrowth [136].
ncRNAs play an important role in neurological functions
and a subset of these transcripts are differentially regulated in
AD and FTD. It is unclear if these transcripts drive disease or
act downstream during neurodegeneration. However, ncRNA
may provide useful information as biomarkers for early AD
detection in peripheral tissues and blood. Diseased or
degenerating neurons may shed extra membrane vesicles con-
taining differentially-expressed RNA and DNA into the cir-
culatory systems that maybe used as biomarkers. In therapeu-
tics, RNA therapy using these vesicles as delivery systems
may provide highly specific outcomes in affecting particular
genes and pathways deregulated in AD and FTD [137]. For
example, anti-ncRNA oligonucleotides could be administered
to increase expression of genes downregulated in disease due
to higher expression of the ncRNAs that target them. For
example, BDNF-AS normally downregulates the neurotrophic
factor BDNF by recruiting chromatin-modifying enzymes to
its locus; recently, Modarresi et al. [138] restored expression
of BDNF by targeting BDNF-AS using modified oligonucle-
otides called antagoNATs. Similarly, lncRNAs may increase
expression of AD and FTD risk-associated proteins by
masking transcripts normally targeted by miRs. Therefore,
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anti-ncRNA could be used to decrease expression of risk
genes. For example, antisense BACE1 antagoNATs could be
designed to counteract ncRNA-mediated mRNA stability of
the BACE1 transcript and target it for degradation.
Potential and Challenges of Epigenetic Therapy
In the previous section, we highlighted the 3 major epigenetic
pathways that are erroneously regulated in AD and FTD, and
possible avenues for intervention using epigenetic pharmaco-
logical agents (Fig. 1). One of the major challenges of bio-
medical neuroscience is the limitation of kind of molecules
that can pass through the BBB. In general, molecules <500
daltons and with fewer than 8 pairs of hydrogen bonds can
pass through the barrier. Other modes of delivery that bypass
the BBB are BBB disruption and intracerebral implantation,
and intracerebroventricular infusion convection enhances dif-
fusion and transnasal delivery; however, the diffusion of drugs
throughout the tissue remains poor [139]. DNMTi and
HDACi molecules have been shown to cross the BBB and
effectively alter epigenetic modifications in the brain
[140–142]. However, the risk–benefit balance has to be con-
sidered in terms of efficacy, toxicity, delivery, and patient
quality. DNMTi nucleoside analogs that insert in the genome
are extensively used in the advanced treatment of cancer.
However, owing to the cyto- and genotoxicity and low stabil-
ity of DNMTi, these molecules may not be appropriate for
continuous treatment for progressive degenerative diseases
like AD and FTD. Therefore, to address adverse side effects
several non-nucleoside allosteric inhibitors of DNMT are
currently under preclinical development [143, 144]. HDACi
are comparatively tolerated better in both human and mice
models with milder side effects in the treatment of different
diseases, despite their broad target range in the genome. The
clinical side effects of HDACi have been well documented
[92, 145]. However, the risk–benefit of long-term usage of
HDACi for nonadvanced stages AD and FTD needs further
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Fig. 1 The general overview of neurodegeneration and possible avenues
for epigenetic therapy. Histone methylation/acetylation levels along with
5-methylcytosine and 5-hydroxymethylcystosine levels undergo age-re-
lated epigenetic drift and potentially deregulate genes associated with
neurodegeneration. Mutations in epigenetic readers, writers and erasers
have been implicated in multiple neurological disorders including cogni-
tive decline. Cellular stress, toxicity and altered SAM levels are associ-
ated with altered promoter DNA methylation in risk-associated genes.
Noncoding RNAs (ncRNAs) are associated with the regulation of
neurodegeneration and neurotropic genes and were found to be differen-
tially regulated in disease models. Together, an altered epigenetic
landscape due to deregulation or mutations in epigenetic readers,
writers and erasers is being portrayed in AD and FTD. Studies have
shown several possible epigenetic therapy intervention avenues. Spe-
cific HDACi have been shown to be beneficial in restoring cognitive
decline and memory formation in disease models due to important
the role of histone acetylation in maintaining neuronal plasticity.
DNMTi (and potentially TET inhibitors), may epigenetically restore
expression of specific genes dysregulated in neurodegeneration. Sim-
ilarly, the anti-mRNA and/or anti-lncRNA could be used to target
deregulated ncRNAs that alter expression of epigenetic and neurode-
generative factors
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investigation; for example, SAHA administration causes re-
active oxygen species-induced genotoxicity [146]. Therefore,
the use of SAHAmay increase risk of cancer. However, a very
recent study showed that the antioxidant Tempol prevents
genotoxicity induced by SAHA and may, potentially, alleviate
the long-term risks of the drug [147]. Hence, further detailed
studies are required to develop safe and effective treatment
protocols using DNMTi and HDACi.
Several carrier molecules capable of transporting small
interfering RNA therapy and cross the BBB have been studied
and developed [139, 148–150]. However, nanoparticle car-
riers designed to cross the BBB have raised several issues
regarding systemic toxicity and neurotoxicity arising from
the carriers molecules and the oligonucleotides themselves;
further studies are required to reduce the immunogenicity and
neurotoxicity of potential ncRNA treatment of brain-related
disorders [151]. In addition, several chemically-modified
anti-ncRNA and oligonucleotides have been developed to
improve the therapeutic efficacy of ncRNA-based therapy
[151]. Owing to the low uptake of therapeutic molecules
through the BBB, several strategies to directly administer
oligonucleotides directly to the brain have also been pro-
posed and some are in advanced clinical validation and
clinical trials [152]. Several promising studies to regulate
levels of mutated BACE1 proteins and altering BDNF
expression levels by direct injection of oligonucleotides in
the brain have been reported.
Little is known about the off-target effects of epigenetic
therapeutics for neurodegeneration. DNMTi and HDACi
may target many genes and genomic regions and reverse
epigenetic marks not associated with disease. ncRNA-based
therapy is more specific compared with other approaches,
but off-target effects must be assessed prior to develop-
ment. Combination therapy may improve the mal-effects
associated with target specificity and some combination
strategies are currently undergoing clinical trials for cancer
therapy [153]. More importantly, the role of epigenetic drift
during aging and associated drivers of disease needs to be
further explored by chronological studies. Early therapeutic
interventions and biomarkers could be developed based on
the specific epigenetic deviations detected early in disease.
An often-neglected area of epigenetics and its role in
disease is transgenerational inheritance. Several new studies
have shown that some DNA methylation and histone mod-
ifications (up to 10 %), along with other small RNA
molecules, escape re-programming during gametogenesis
and fertilization, and can be passed both maternally or
paternally to the next generation [154, 155]. Importantly,
diet, stress and other environmental factors do play a role
in transgenerational inheritance of neurological disorders in
mainly mouse models [154]. Further studies are required to
determine if AD or FTD risk factors are also transgenera-
tionally inherited and increase risk of disease.
Unlike genetic changes that drive disease, a large number
of epigenetic variations are readily reversible with the use of
drugs. Recent studies have tied the role of epigenetic modifi-
cations directly to AD and FTD and opened up the possibility
of applying epigenetic pharmacology to neurodegenerative
diseases and other brain-related disorders.
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